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An analysis of phosphorylation changes that occur during cancer progression would provide
insights into the molecular pathways responsible for a malignant phenotype. In this study we
employed a novel coupling of 2-D liquid separations and protein microarray technology to reveal
changes in phosphoprotein status between premalignant (AT1) and malignant (CA1a) cell lines
derived from the human MCF10A breast cell lines. Intact proteins were first separated according
to their pI and hydrophobicities, then arrayed on SuperAmine glass slides. Phosphoproteins
were detected using the universal, inorganic phospho-sensor dye, Pro-Q Diamond. Using this
dye, out of 140 spots that were positive for phosphorylation, a total of 85 differentially expressed
spots were detected over a pH range of 7.2–4.0. Proteins were identified and their peptides
sequenced by MS. The strategy enabled the identification of 75 differentially expressed phos-
phoproteins, from which 51 phosphorylation sites in 27 unique proteins were confirmed. Inter-
estingly, the majority of differentially expressed phosphorylated proteins observed were nuclear
proteins. Three regulators of apoptosis, Bad, Bax, and Acinus, were also differentially phospho-
rylated in the two cell lines. Further development of this strategy will facilitate an understanding
of the mechanisms involved in malignancy progression and other disease-related phenotypes.
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1 Introduction
Breast cancer is the most frequently diagnosed cancer in
women. More than 200 000 new cases of breast cancer, with
over 41 000 deaths, were expected in the United States in
2008 [1]. Breast cancer related deaths have declined by ap-
proximately 2.3% from 1990 to 2002 primarily due to earlier
detection awareness as well as improved treatment. While
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the five-year survival rate has increased to 98% for local-
regional disease, it is only 26% for women with distant
metastases [1]. Understanding the molecular mechanisms
that underlie breast cancer development and progression to
malignancy may uncover better therapeutic targets with
potential utility to further decrease breast cancer mortality.
Aberrations in cellular signaling pathways have been
associated with cancer development and progression, as
cancer cell survival and proliferation rates increase, and as
cancer cells become increasingly evasive to the immune sys-
tem [2–4]. Growth factor signals are propagated from the cell
surface intracellular milieu by signaling pathways, involving
a variety of kinases such as membrane receptor kinases
(EGFR, VEGF) and cytoplasmic kinases (ERK, MEK, Ras,
PI3-K, and mTOR) [5]. In cancer, these signaling pathways
are often dysregulated, resulting in a phenotype character-
ized by unfettered cell growth and increased invasive poten-
tial. Cellular signaling is largely controlled by transient,
PTMs of signaling proteins, which alter their ability to bind
and interact with downstream effectors [4–6]. Protein phos-
phorylation is one such modification that primarily acts as a
molecular switch to activate or deactivate cellular signaling
cascades [4, 7, 8]. A recent review by Krueger et al. [9] lists
several phosphorylated proteins that are known to contribute
to oncogenesis or are used in the context of a cancer bio-
marker. Proteins from all cellular compartments are repre-
sented in this list including histones, HDACs, MAP kinases,
Akt, PTEN, EGFRs, and ILK.
A variety of techniques have been used to study phos-
phorylation expression on a large scale [10, 11]. One such
technique involves incubation of cells with radioactive 32P
followed by 2-DE [12]. Although able to detect a wide dy-
namic range of phosphoproteins, this method requires
handling of radioactive orthophosphate which makes it less
favorable. In addition, the dependence on turnover rates at
which the orthophosphate is incorporated into proteins may
reduce sensitivity of this technique. The use of monoclonal
and polyclonal antibodies specific to phosphorylated proteins
to detect global phosphoprotein patterns on gels [13] cir-
cumvents the use of radiolabels. However, current available
phosphoserine-specific and phosphothreonine-specific anti-
bodies are not always reliable and cannot detect phospho-
proteins where steric hindrance prevents antibody binding.
More recently, a novel small molecule phosphosensor dye
has been reported for detecting phosphoproteins on both gel
and microarray platforms [14–17]. This dye is able to detect
phosphotyrosine, serine, and threonine residues and can
discriminate between thiophosphorylation and sulfation.
Gel-based methods have been considered the method of
choice in studying global protein expression, but more
recently developed techniques have focused on liquid-based
methods due to the ease of coupling to mass spectrometers
for protein identification [18–21]. The liquid-based method
most frequently used for phosphoprotein analysis in com-
plex samples involves shotgun proteomics where a complex
protein mixture is first digested and enriched for phospho-
peptides [22–24]. An enrichment step is often necessary
since phosphopeptide ionization is typically suppressed in
the presence of many nonphosphorylated peptides present
in a complex sample. The enriched peptides are then ana-
lyzed by LC-MS/MS with comprehensive database searching
to confirm identity and elucidate the phosphorylation site. A
variety of enrichment methods have been developed ranging
from immobilized metal affinity chromatography [25, 26] to
amphoteric oxide-based enrichment, frequently using tita-
nium or zirconium dioxide [27], as well as antibody-based
enrichment. While shotgun proteomics is a high-throughput
method at the experimental front, it is very time-consuming
at the analysis end since data must be closely examined for
possible false positives and negatives [28].
To overcome some of these limitations, we have been
developing the coupling of comprehensive 2-D liquid
separation methods to protein microarray technology. Per-
formance evaluation of arrays generated from 2-D liquid
separations has been reported elsewhere [29]. We have used
this combined liquid separation and protein microarray
strategy previously to assess the phosphorylation status of all
proteins in a cell line that was treated with a specific protein
kinase inhibitor [30]. While that study was successful in
highlighting phosphorylation changes caused by experi-
mentally perturbing a specific biological pathway, there are
currently no reports investigating such changes in naturally
occurring disease states. A study comparing phosphorylation
status in disease states may have utility in elucidation of
pathways that play a role in the progression of the disease.
A xenograft model of human breast disease progression
has been developed from the MCF10A breast epithelial cell
lines. Selected cell lines within the series are representative
of normal, premalignant, and malignant phenotypes [31–33].
T24 c-Ha-ras oncogene-transfected MCF10A cells (MCF10A-
neoT) form small, flat nodules in Nude/Beige mice which
persist for the life span of the host and sporadically progress
to carcinomas. A variant cell line (MCF10AT1), derived from
one xenograft, not only forms simple differentiated ducts
which persist in xenografts and sporadically progress to car-
cinoma, but also forms intermediate proliferative lesions
resembling proliferative disease without atypia, atypical
hyperplasia, and carcinoma in situ. By establishing cells in
culture representing different stages in progression of
MCF10AT through atypical hyperplasia to carcinoma, inter-
ruption of progression has been made possible. These cell
lines continue to progress when reimplanted in vivo in
immune deficient mice but are sufficiently stable in vitro to
provide the tools essential for the genetic analysis of pro-
gression. MCF10AT cells express low levels of estrogen
receptor (ER) and estradiol (E2) accelerates progression of
the premalignant xenograft lesions. Fully malignant variants
(MCF10CA lines), some of which are metastatic have also
been recently derived.
In this study, we compared the phosphoproteome of
premalignant (MCF10AT1) and malignant (MCF10CA1a
c11) cell lines using a 2-D liquid-phase separation method
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coupled to protein microarray technology. These two cell
lines were chosen because they represent the initial (pre-
malignant) and final (malignant, metastatic) stages of breast
disease. The naturally occurring, arrayed proteins were pro-
bed with the small-molecule phosphosensor dye, Pro-Q Dia-
mond, and antiphosphotyrosine antibodies. The strategy
enabled us to detect and identify differentially expressed
phosphoproteins and to determine specific changes asso-
ciated with the premalignant and malignant phenotypes.
2 Materials and methods
2.1 Sample preparation
2.1.1 Cell lines
The premalignant AT1 cell line (MCF10AT1) and malignant
CA1a cell line (MCF10CA1a c11) were both derived from the
MCF10A human breast cell line and were maintained and
prepared as previously described [31, 33].
2.1.2 Cell lysis, buffer exchange, and protein
quantitation
Cells were mixed with lysis buffer containing 7 M urea, 2 M
thiourea, 100 mM DTT, 2% n-octyl G-D-glucopyranoside
(OG), 10% glycerol, 10 mM sodium orthovanadate, 10 mM
sodium fluoride (all from Sigma, St. Louis, MO), 0.5% Bio-
lyte ampholyte (BioRad, Hercules, CA), and protease inhibi-
tor cocktail (Roche Diagnostics, Mannheim, Germany) with
vortexing at room temperature for 1 h. Cellular debris and
other insoluble materials were removed by centrifuging the
mixture at 80 0006g for 1 h 15 min. The supernatant was
subjected to buffer exchange in order to replace the lysis
buffer with start buffer (SB) (composition described later) for
chromatofocusing (CF) using a PD-10 G-25 column
(Amersham Biosciences, Piscataway, NJ). The protein con-
centration was determined using the Bradford Protein Assay
kit with BSA (BioRad) standard.
2.1.3 Chromatofocusing (CF)
The CF experiment was performed using a Beckman System
Gold model 127 pump and 166 UV detector module (Beck-
man-Coulter, Fullerton, CA) with an HPCF-1D prep column
(250 mm length64.6 mm id, Eprogen, Darien, IL). A linear
pH gradient was generated using a combination of SB com-
posed of 6 M urea, 25 mM Bis-Tris, and 0.2% OG and elution
buffer (EB) containing 6 M urea, 0.2% OG, and 10% poly-
buffer 74 (Amersham Biosciences). Saturated iminodiacetic
acid (Sigma) was used to adjust the pH of SB at 7.2 and EB at
3.9. The column was first equilibrated in SB until the pH of
the column was the same as SB by monitoring with a post-
detector online assembly of a pH-flow cell (Lazar Research
Laboratories, Los Angeles, CA). After equilibration, ,10 mg
of sample was loaded onto the column at a low flow rate to
allow for interactions of the proteins with the binding sites.
Once a baseline was achieved, solvent flow was switched to
EB and the flow rate was set to 1 mL/min for CF fraction
collection at the intervals of 0.2 pH units along the linear
gradient, where the elution profile was recorded at 280 nm.
At the end of the gradient, the column was flushed with 1 M
sodium chloride (Sigma) to remove any proteins still bound
to the column. All collected samples were stored at 2807C
until further analysis.
2.1.4 Nonporous silica RP-HPLC
Each CF fraction was loaded onto a nonporous silica RP
(NPS-RP) HPLC column for further separation. An
ODSIII-E (8633 mm2) column (Eprogen) packed with
1.5 mm NPS was used to achieve high separation efficiency.
The separation was performed at a flow rate of 1 mL/min
using a water/ACN solvent system (A was 0.1% TFA in
deionized water and B was ACN and 0.1% TFA) and the
gradient used was: 5–15% B in 1 min, 15–25% B in 2 min,
25–31% B in 3 min, 31–41% B in 10 min, 41–47% B in
3 min, 47–67% B in 4 min, 67–100% B in 1 min, followed
by maintaining the system at 100% B for 3 min. Separa-
tion was monitored at 214 nm using a Beckman 166 model
UV detector (Beckman-Coulter). Purified protein peaks
were collected in deep-well 96-well plates using an auto-
mated fraction collector (model SC 100; Beckman-Coulter),
controlled by in-house-designed DOS-based software. The
column was maintained at 607C during separation to
enhance reproducibility, speed, and resolution. Following




All fractions were transferred to shallow-well print plates
(BioRad) and were lyophilized to dryness. The samples were
resuspended in printing buffer, consisting of 62.5 mM Tris-
HCl (pH 6.8), 1% w/v SDS, 5% w/v DTT, and 1% glycerol in
16PBS, and were left agitating on an orbital shaker over-
night. Printing was accomplished by depositing five droplets
of ,500 pL each per fraction using a piezoelectric dispenser
(Nanoplotter 2, GeSiM). Superamine glass slides (TeleChem
International) were utilized for printing. Distance between
spots was maintained at 600 mm and spot sizes were found to
be ,450 mm. Prior to processing all slides were kept sealed
in a dessicator.
2.2.2 Array processing with Pro-Q diamond dye
Glass slides were blocked overnight in 1% BSA (Roche) in
16PBS-T (0.1% Tween 20). They were then incubated for
1 h in Pro-Q Diamond phosphoprotein gel stain (Invitro-
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gen). The slides were then washed in destaining solution
(Invitrogen) three times for 10 min each, then rinsed with
nuclease free water, and dried by centrifugation. The slides
were scanned in the green channel using an Axon 4000A
scanner, and GenePix Pro 6.0 software (Molecular Devices,
Sunnyvale, CA) was used for data acquisition and analysis.
Spots were considered to be positively fluorescent if back-
ground subtracted intensity of the spot was X2 the local
background intensity around the spot.
2.2.3 Array processing with antityrosine antibodies
Glass slides processed and scanned with Pro-Q diamond dye
were rehydrated and then incubated in mouse monoclonal
antiphosphotyrosine, 4G10 clone antibody (Upstate, Char-
lottesville, VA) diluted to 2 mg/mL in probe buffer (5 mM
magnesium chloride, 0.5 mM DTT, 0.05% Triton X-100, and
5% glycerol in 16PBS). After primary incubation the slides
were washed (five times, 5 min each) in probe buffer. Sec-
ondary incubation was performed for 1 h using donkey anti-
mouse antibody conjugated to fluorescent cy5 at a con-
centration of 1 mg/mL in probe buffer. The slides were finally
washed (five times, 5 min each) in probe buffer and scanned
in the red channel. Once again, spots were considered to be
positively fluorescent if background subtracted intensity of
the spot was X2 the local background intensity around the
spot.
2.3 Removal of SDS from samples
Prior to digestion and protein identification by MS samples
were cleaned using Detergent-OUT SDS-300 spin columns
(G-Biosciences, St. Louis, MO) to remove residual SDS that
was present during reconstitution into print buffer as per the
user guide. In short, spin columns were inverted to re-sus-
pend resin and liquid was drained off by spinning at 10006g
for 10 s. Columns were then equilibrated with 1.5 mL
deionized water which was collected in a centrifuge tube and
discarded. Sample was then applied to the spin columns and
was let to stand for 5 min. After the columns were loaded
they were centrifuged at 10006g for 30 s and the SDS-free
sample was collected in a centrifuge tube.
2.4 Trypsin digestion
The samples were dried down to 10 mL, and then 40 mL of
100 mM ammonium bicarbonate and 10 mL of 10 mM DTT
were added to sample. The samples were incubated at 607C
for 20 min to allow for reduction of disulfide bonds. 0.5 mL of
TPCK modified sequence grade trypsin (Promega) was
added and the samples were incubated at 377C overnight.
Digestion was stopped by adding 1 mL of TFA to the digestion
mixture.
2.5 Peptide sequencing by LC-MS/MS
Digested samples were separated by a capillary RP column
(MagicAQ C18, 0.16150 mm2) (Michrom Biosciences,
Auburn, CA) on a Paradigm MG4 micropump (Michrom
Biosciences) with a flow rate of 300 nL/min. The gradient
was started at 3% ACN, ramped to 35% ACN in 25 min, 60%
ACN in 15 min, 90% in 1 min, maintained at 90% ACN for
1 min, and finally ramped back down to 3% in another
1 min. Both solvents A (water) and B (ACN) contained 0.1%
formic acid. The resolved peptides were analyzed on an LTQ
mass spectrometer (Thermo, San Jose, CA) with a nano-ESI
platform (Michrom Biosciences). The capillary temperature
was set at 2007C, the spray voltage was 2.5 kV, and the capil-
lary voltage was 20 V. The normalized collision energy was
set at 35% for MS/MS. The top five peaks were selected for
CID. Precursor selection was based upon a normalized
threshold of 30 counts/s. MS/MS spectra were searched
using the SEQUEST algorithm incorporated in Bioworks
software (Thermo) against the Swiss-Prot human protein
database with trypsin as the enzyme. Additional search pa-
rameters were as follows: (i) allowing two missed cleavages;
(ii) possible modifications, oxidation of M and phosphoryla-
tion of S, T, and Y; (iii) peptide ion mass tolerance 1.50 Da;
(iv) fragment ion mass tolerance 0.0 Da; (v) peptide charges
11, 12, and 13. The filter function in Bioworks browser was
applied to set a single threshold to consider peptides
assigned with Xcorr values as follows: 1.5 for singly charged
ions, 2.5 for doubly charged ions, and 3.5 for triply
charged ions.
3 Results and discussion
The overall strategy we used for the large-scale analysis of
cellular protein phosphorylation status is outlined in Fig. 1.
Fractionation of the sample to reduce complexity, was
achieved by separation in two dimensions, initially by CF
(according to the protein pI), and then by RP-HPLC, accord-
ing to their hydrophobicity. Fractions were carefully collected
by peaks and each cell line resulted in approximately 1200
fractions after the complete 2-D separation. The fractionated
proteins were then printed onto microarrays and analyzed by
hybridization with a universal phosphoprotein stain, and
with antibodies specific to phosphorylated tyrosine residues.
Hundred forty spots were found to exhibit a positive re-
sponse to the Pro-Q dye. Antiphosphotyrosine antibodies did
not give any additional information compared to the Pro-Q
Diamond dye suggesting that sensitivities of both forms of
detection were comparable. It is therefore possible to solely
use the Pro-Q Diamond dye for detection purposes, hence
saving on the high antibody-based detection costs. However
anti-phosphotyrosine antibodies would be preferred in cases
where only signaling cascades controlled by tyrosine phos-
phorylation are being sought. Sequence analysis of specific
phosphoproteins for confident identification was achieved by
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Figure 1. Microarray strategy
for global evaluation of phos-
phorylation changes as a func-
tion of disease.
peptide sequencing using MS/MS. This combinatorial
approach overcomes many of the limitations inherent in
single-method analyses. Phosphorylation sites have proved
difficult to identify by MS alone due to poor ionization effi-
ciency and low abundance of phosphopeptides. Additionally,
mass spectrometric methods are not reliable for assessing
phosphorylation in a time-efficient manner. The proposed
strategy is high-throughput in nature and a method of choice
in initial screening to find differentially expressed proteins
over the whole proteome in a sample of interest.
3.1 2-D liquid separation and microarray
reproducibility
A comparison of the 2-D liquid separation (pH 4.0–7.2) is il-
lustrated in Fig. 2. On the left is a 2-D UV map of the pre-
malignant AT1 cell line, while on the right is the same for the
malignant CA1a cell line. In the center is the comparison of
the two maps. It can be seen that while the overall 2-D maps
are very similar for both cell lines, several differences are
revealed. In particular, many proteins are highly expressed in
the malignant cell line, CA1a in the pH range 6.6–7.0 (cor-
responding to lanes 13 and 14 in Fig. 2). Most of these pro-
teins elute during the first half of the HPLC run. Sixty-nine
proteins were detected in the pH range 6.6–7.0 based upon
LC-MS/MS experiments in the malignant CA1a cell line.
Comparative screening of the protein microarrays was
achieved using the global phosphoprotein stain Pro-Q Dia-
mond and antibodies specific to phosphorylated tyrosine
residues. To investigate the binding properties of Pro-Q
phospho-stain and antibodies, protein, and peptide stand-
ards were printed on SuperAmine slides. The slides were
then probed initially with the phosphoprotein stain, Pro-Q
Diamond, followed by a monoclonal anti-phosphotyrosine
antibody (Fig. 3a). While ovalbumin and b-casein solely con-
tain phosphoserine and phosphothreonine residues and
therefore fluoresce green as a result of staining, the phos-
photyrosine peptide (pY) mixture appears red. This occurs
because the antibody for phosphotyrosine displaces the Pro-
Q and binds to the phosphotyrosine residues present in that
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Figure 2. 2-D liquid separation
of premalignant AT1 and malig-
nant CA1a cell lines. Each lane
represents a pH fraction differ-
ent by 0.2 units. Vertical axis
refers to the retention time dur-
ing the separation. Intensity of
the bands correspond to peak
heights which ranged from a
value of 100–990 mV. Difference
between premalignant and
malignant sample appears in
the middle panel.
Figure 3. Detecting phosphoproteins on microarrays using Pro-Q Diamond dye and antiphosphotyrosine antibodies. (a) A study done with
standards where ovalbumin, B-casein, and a mixture of tyrosine phosphorylated proteins were used. The figure is shown in gray scale but when
probed with both Pro-Q and anti-pY antibody, the fluorescent labels are such that solely pY proteins appear red, a mixture of pY and pS or pT
appear yellow and solely pS or pT appear green. (b) An image of a section of a protein microarray-containing fractionated proteins from a
malignant breast whole cell lysate.
spot. Subsequently, a red fluorescently tagged secondary
antibody (in this case, an anti–anti-phosphotyrosine antibody
conjugated to cy5) binds to the primary anti-phosphotyrosine
antibody resulting in a red spot. A section of microarray
generated by spotting of premalignant AT1 and malignant
CA1a is also shown in Fig. 3b. It can be seen that several
fluorescing protein spots indicate the presence of phospho-
rylation. More importantly, Fig. 3b shows that the protein
contents that were being used in the 2-D separation were
sufficient for microarray analysis.
Given the dynamic nature of cellular phosphorylation,
we undertook a reproducibility study in order to better indi-
cate the biological relevance of our phospho-profile findings.
Three separately grown CA1a cell line batches and two sepa-
rately grown AT1 cell line batches were independently sub-
jected to the entire analytical strategy, including 2-D liquid
separations, protein microarray, and MS. Several pH ranges
were selected to assess reproducibility for all samples.
Figure 4 illustrates the results obtained. When looking at
the CF result (Fig. 4a), where pH fractions as collected could
be monitored online for pH via a pH electrode assembly, it
can be seen that for all separations a reproducible pH gra-
dient was obtained. Furthermore, it can be seen for the CA1a
cell line that all separated samples resulted in very similar
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Figure 4. Comprehensive study
to assess reproducibility of the
method. (a) CF chromatograms
of three ca1a separations are
shown on the left and of two AT1
separations are shown on the
right. In all cases 4.5 mg of sam-
ple was loaded (one AT1
separation was performed with
only 3 mg of total protein). Co-
plotted with the chromatograms
are pH profiles to illustrate that
the pH gradient was consistent
in all separations. (b) Second di-
mension chromatograms of all
batches of cell lines for pH rang-
es 6.4–6.2 and 7.2–7.0. Arrows
along the chromatogram illus-
trate peaks that are shown in
subsequent microarray data. (c)
Array images of samples from
pH fractions 7.2–7.0, 6.4–6.2, and
5.4–5.2 to illustrate reproducibil-
ity throughout the separation
space. (d) Sections of micro-
array data showing an example
of reproducible positive spots
that are unique to ca1a (pH 5.4–
5.2, retention time 28 min) and
that are found in all cell lines
(pH 6.4–6.2, retention time
26 min). Peaks corresponding to
the positive spots found in all
cell lines are indicated by arrows
in Fig. 4b.
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and reproducible separation profiles. Similar separation
profiles were also observed for the two batches of AT1 cell
lines run. However, although the peak patterns were very
similar they were not identical as in the case of CA1a. This
difference was explained by the fact that while all other
samples were loaded at a total protein content of 4.5 mg, one
of the AT1 samples had a lower total protein content of only
3 mg which resulted in an overall lower signal during the
acquisition of the chromatogram. A comparison of the two
batches of chromatograms suggests some subtle differences
between CA1a and AT1 particularly in the higher pH range
of about 7.0–6.2 and in the lower pH range around 5.6–5.2.
In order to further assess these subtle differences,
selected pH ranges were subjected to NPS-RP-HPLC. Exam-
ple chromatograms illustrating these separations are shown
in Fig. 4b. A high level of reproducibility is seen in both the
independently grown batches of CA1a and AT1 samples an-
alyzed. Furthermore, the subtle differences that were seen in
the CF profiles are better visualized in the second dimension.
It can be seen that the malignant CA1a cells contains more
hydrophilic protein peaks relative to the premalignant AT1
cells.
Fractionated samples from the second dimension were
arrayed on glass slides and probed with Pro-Q diamond dye
to assess the phosphorylation status of the proteins. It is
possible that while the chromatograms appear reproducible,
the phosphorylation status of the protein may not be the
same, making it necessary to assess reproducibility at the
microarray level. Five slides were printed and probed with
Pro-Q dye to assess the reproducibility of the printing and
hybridization process. Figure 4c shows slide images of spots
that were arrayed from selected pH ranges. It can be seen
that all spots show consistently similar size and shape indi-
cating that the printing process is consistent and reproduci-
ble. Slight variation in background intensities between the
slides can be attributed to variation in slide surfaces and
experimental variation during hybridization. However, these
variations do not alter the number of positive spots of the
array and therefore do not affect the results significantly.
Figure 4d illustrates sample biological reproducibility data
obtained using the three CA1a and the two AT1 batches. It
can be seen that for the pH range 6.4–6.2 there is a phos-
phorylated protein that elutes around retention time 26 min
for all samples of CA1a and AT1 that were analyzed. How-
ever, for the pH range 5.2–5.0 there is a phosphoprotein
(retention time 28 min) that is present only in CA1a sam-
ples. The reproducibility experiment revealed that con-
sistent, differential phosphoprotein expressions were
achievable across samples and batches.
It was also important to verify that the proteins present in
consistently detected spots on the microarray were in fact the
same proteins across samples. To this end, SDS was removed
from selected sample fractions to be printed on arrays (as
outlined in Section 2), proteins were trypsinized and then
analyzed by MS/MS. Table 1 shows the protein IDs of the two
spots that appeared positive for the CA1a samples in the pH
range 6.4–6.2. In all cases, the proteins present in specific
microarray spots were the same proteins. These analyses
show that the strategy and the techniques are highly repro-
ducible and confirm that the differential expression of spe-
cific phosphoproteins is maintained in the MCF10A tumor
progression model.
3.2 Cell-associated phosphoprotein profiles
All spots representing the same region of the 2-D UV map
from the two cell lines were compared to identify differential
phosphorylation profiles. Premalignant and malignant sam-
ples were printed on microscopic glass slides with a chemi-
cally modified amine surface for studies with Pro-Q and
antiphosphotyrosine antibodies. For each comparison, at
least five replicate slides were processed. Of the phospho-
proteins whose modification sites were identified, 11 pro-
teins were seen to be phosphorylated in the premalignant
cell line but not the malignant cell line, and 16 proteins were
seen to be phosphorylated in the malignant cell line but not
the premalignant cell line. Examples of the differences
observed, together with the identity of the protein as deter-
Table 1. Protein IDs and peptides identified for selected microarray spots depicted in Fig. 4c
Sample Protein ID Score Peptides sequences Coverage
Ca1a_spot1 Lamin-A/C 400 15 25
Ca1a_spot2 Lamin-A/C 410 19 33
Protein disulfide-isomerase A3 precursor 370 15 31
Ca1a_spot1 Lamin-A/C 450 20 33
Ca1a_spot2 Protein disulfide-isomerase A3 precursor 380 15 29
Lamin-A/C 340 17 30
Ca1a_spot1 Lamin-A/C 410 18 33
Ca1a_spot2 Lamin-A/C 480 20 34
Protein disulfide-isomerase A3 precursor 360 14 30
AT1_spot1 Lamin-A/C 410 19 32
AT1_spot2 Protein disulfide-isomerase A3 precursor 240 11 21
Lamin-A/C 180 8 14
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mined by MS/MS, are illustrated in Fig. 5. In some cases a
protein eluted over multiple peaks due to diffusional broad-
ening during sample collection. These proteins appear in
multiple spots in the figures. Furthermore, there were
instances where more than one phosphoprotein eluted at al-
most the same retention time. In these cases both protein
identities are shown in the figure. Overall, 51 phosphoryla-
tion sites from a total of 27 proteins were identified over a pH
range of 7–4. In addition, 47 previously reported phospho-
proteins were also identified, but no phosphorylation site
verification was obtained through the MS/MS data. Although
dynamic exclusion was used to ensure that peptides eluting
over a longer time were not continuously selected for MS/MS
analysis, it is possible that more sites were not identified due
to the low signal intensities of phosphopeptides which ren-
dered them undetectable using the top five ion peak selection
used during our MS/MS runs. Furthermore, three phospho-
proteins were shown to not be differentially expressed in the
two cell lines. All phosphoproteins identified with site ver-
ification are listed in Table 2, along with information about
the number of peptides and protein coverage pertinent to
protein identification. Table 1 of Supporting Information
also lists all phosphoproteins identified without site verifica-
tion. Site verification was not possible for these peptides due
to low sample amounts. We did investigate phosphopeptide
enrichment using titanium dioxide tips to improve yield, but
without improvement. The results presented herein corre-
late well with previous work where approximately 155 spots
in a 2-D gel stained positive for phosphorylation using the
Pro-Q Diamond dye [34]. In another study about 100 proteins
showed a change in phosphorylation upon stimulation of
fibroblast cells where detection on 2-D gels was facilitated by
using antiphosphotyrosine and antiphosphoserine anti-
bodies [35]. Our proposed strategy bypasses problems asso-
ciated with 2-DE while providing equivalent and com-
plementary information about protein phosphorylation at
the intact protein level. This can be especially useful when
site verification from mass spectrometric data is difficult due
to poor phosphopeptide spectra, which is often the case.
The pie chart in Fig. 6 shows the cellular distribution of
proteins whose modification sites were verified regardless of
whether the phosphorylation was found in the premalignant
or malignant cell line. Interestingly, out of the 27 differen-
tially phosphorylated proteins whose modified sites could be
verified by MS/MS, 18 were nuclear proteins. This trend of
differential phosphoprotein expression in the nuclear region
was also observed for those proteins whose sites were not
verified. Closer examination of the proteins showed that the
malignant CA1a cell line exhibited increased phosphoryla-
tion of nuclear proteins compared to the premalignant AT1
cell line.
It should be noted that a majority of the proteins that
were detected and identified as being differentially phos-
phorylated in this work are of high to medium abundance. In
this work, we observed 85 differentially expressed spots (cor-
responding to a total of 75 phosphoproteins of which we
Figure 5. Selected microarray
images showing comparison of
spots where differential phos-
phorylation was observed be-
tween premalignant and malig-
nant breast cell lines over differ-
ent pH regions. Protein IDs as
determined by MS/MS are
shown beside the image. For
some proteins, multiple con-
secutive spots light up due to
diffusional broadening during
peak collection. In some cases
more than one phosphoprotein
was identified in the same col-
lected fraction. In such cases,
both phosphoproteins are list-
ed.
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7.0–6.8 4 18 S138 (AALLKApSPK) none X Nucleus
Q14978 Nucleolar
phosphoprotein p130





7.0–6.8 2 13 T24 (pTDGKVFQFLNAK) pT83, pS86 X
Q9BQ48 39S ribosomal
protein L34
7.0–6.8 3 26 S89 (pSLSH) X Mitochondria
Q9Y3U8 60S ribosomal
protein L36
7.0–6.8 4 27 T17 (VpTKNVSK) X
P62318 Small nuclear
ribonucleoprotein Sm D3
7.0–6.8 1 7 S93 (NQGpSGAGRGK) X Nucleus
Q13428 Treacle protein 7.0–6.8 4 4 S959, S964 (IAP-
KApSMAGApSSSK)





6.8–6.6 2 4 T234 (QDKIQpTGEKHEK) none X Nucleus
P02545 lamin A/C 5.4–5.2 39 55 S17, S18 (SGA-
QApSpSTPLSPTR), S390,
T394 (LRLpSPSPpTSQR)
S22, S390, S392, S652. By similarity





5.2–4.8 2 4 T2727 (VpTFPKMKIPK) S264, S312 X Nucleus




5.2–5.0 1 2 T391 (KGpTNIILNIGR) none X Membrane
Q14562 ATP-dependent
helicase DHX8
5.2–5.0 2 5 T914, T915 (DEMLpTp-
TNVPEIQR)
none X Nucleus
Q02539 histone H1.1. 5.2–5.0 2 6 T151 (KSVKpTPK), T203
(pTAKPK)
none X Nucleus
Q03252 lamin B2. 5.2–5.0 13 20 S402, S401, S400
(ATSpSpSpSGSLSATGR)
similarity S427 X Nucleus
P02545 lamin A/C 5.2–5.0 36 56 S390, S392, T394
(LRLpSPpSPpTSQR)
S403, S404, S406, S407
(ApSpSHpSpSQ
TQGGGSVTK)
S22, S390, S392, S652. By similarity
S407, S496, T505, S507, T510,
X Nucleus
P02545 lamin A/C 5.2–5.0 32 48 S390, S390, T394,
(LRLpSPpSPpTSQR)
S22, S390, S392, S652. By similarity














5.0–4.8 11 9 T2727 (VpTFPKMKIPK) experimental S264, S312 X Nucleus
Q07812 apoptosis regulator
BAX, membrane isoform a
5.0–4.8 2 6 T135, T140
(pTIMGWpTLDFLR)
none X Membrane
P16403 histone H1.2 5.0–4.8 3 18 S112 (KAApSGEAK) similarity S36 X Nucleus
P08779 cytokeratin 16 5.0–4.6 3 8 Y249 (EELApYLR) none X Cytoskeleton
P05787 Cytokeratin 8 5.0–4.8 20 41 S43 (VGSpSNFR) S24, S74, S432, S451. By Similarity
S9, S13, S22, T26, S27, S34, S37,




5.0–4.8 2 1 S383, S384, S389
(MpSpSPEDDpSDTK)
by similarity S344 X Nucleus
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P28001 histone H2A.a 4.8–4.6 3 27 T120 (pTESHHK) S2, T121 X Nucleus
O14929 histone
acetyl-transferase
type B catalytic subunit




P08621 U1 small nuclear
ribonucleoprotein 70 kDa
4.8–4.6 12 26 S226 (YDERPGPpSPLPHR) S226 X Nucleus
P08670 vimentin. 4.8–4.6 25 56 S54, S55 (SLYApSpSPGG-
VYATR), S28, Y29
(pSpYVTTSTR)
S5, S7, S8, S9, S10, S39, S42,
S56, S72, S73, Y117, S420,
S430, T458, S459. By similarity




inducer in the nucleus
4.6–4.4 8 6 S1004 (TAQVPpSPPR) S240, S243, S365, S386, S388, S657,
S661, S676, S1004, T414, T682.
By similarity S384
X Nucleus
P20700 lamin B1. 4.2–4.0 12 23 S395 (LSPSPSpSRVTVS-
RASSSR)
T20, S23, S391 X Nucleus




S22, S390, S392, S652. By similarity
S407, S496, T505, S507, T510,
X Nucleus
Figure 6. Pie chart illustrating subcellular location of phospho-
proteins whose phosphorylation sites were confirmed by MS in
both the AT1 and CA1a cell line combined. Closer examination
showed a majority of these phosphoproteins to be present in the
CA1a cell line (see Table 1).
were able to identify phosphorylation sites from 27 pro-
teins) although we observed a total of 140 protein spots
that responded to Pro-Q Diamond dye. The information
that can be found from this work can therefore shed light
on the downstream effects of phosphorylation signaling
cascades. However, information about the very first
changes that occur in a pathway were not detected since
these occur on molecules with very low copy numbers in
the cell which are generally below the detection limit of the
Pro-Q dye.
An interesting phenomenon that we observed in our
experiments was the shifts in pI due to phosphorylation. For
example, in Table 1 it can be seen the protein lamin A/C
appears multiple times. This protein was seen over more
than one pH range. In addition it was found that the phos-
phorylation sites on the protein that were detectable using
the unenriched samples were different for each pH range
where the protein was observed. This phenomenon illus-
trates an important aspect about the effect of PTMs on pro-
tein pI. Previous work from our laboratory has shown that
addition of a PTM on a protein changes the protein pI [36]
and microarray data from this study further support these
findings.
3.3 Functional grouping of phenotype-associated
phosphoprotein profiles
Many of the differentially expressed phosphoproteins iden-
tified in this study fall under distinct categories with respect
to the biological processes in which they are involved. Fig-
ure 7 summarizes these proteins according to their func-
tional role in cellular processes. The majority of differen-
tially phosphorylated proteins were found to be upregulated
in the malignant CA1a cell line. A few key proteins that
were found to be more phosphorylated in the nonmalignant
AT1 appear in a box with broken lines in the same figure.
Transcriptional and translational proteins were in the
majority, while mitotic and apoptosis-related proteins were
also represented. In addition, a separate class of enzymes as
well as proteins that maintain cytoskeletal integrity were
observed to change their phosphorylation state as a function
of malignant cellular phenotype. A discussion of some of
the known roles of the phosphoproteins identified in this
study is given below.
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Figure 7. Functional classification of
proteins differentially phosphorylated in
the premalignant and malignant breast
cell lines. Majority of phosphoproteins
were found in the malignant, CA1a. In
cases where a phosphoprotein was
found in AT1 and not CA1a, it appears in
a box with broken lines.
3.3.1 Apoptotic signaling
Proteins involved in the regulation of apoptosis are impor-
tant determinants of cell proliferation and survival in malig-
nant phenotypes. Stimulatory growth factor signaling and
inhibitory stress factors initiate signal transduction pathways
that regulate apoptosis via altering the phosphorylation of
key regulating proteins. Three proteins important in the
regulation of apoptosis, Bad, Bax, and Acinus were differen-
tially phosphorylated in AT1 and CA1a cells. While phos-
phorylated acinus was only found in CA1a, Bad, and Bax
phosphorylated forms were uniquely seen in AT1.
Growth factor induced phosphorylation of BAD protects
cells from apoptotic stimuli. PI3K/Akt, Ras/MAPK/Rak, and
PKA pathways all phosphorylate BAD. When serines at 112,
136, and 155 are phosphorylated, BAD is bound to an inactive
complex [37] In LNCaP human prostate cancer cells, phos-
phorylated sites necessary for activity varied with the survival
signaling pathway [38]. Because malignant cells would be
expected to have diminished sensitivity to apoptotic signals,
phosphorylation of BAD in AT1 relative to CA1a suggests that
additional sites other than the previously reported critical
three serines are phosphorylated in AT1 cells.
The consequence of phosphorylated threonines at 135
and 140 in Bax in AT1 cells is unknown. Both apoptotic and
anti-apoptotic activities have been associated with phospho-
rylation at different sites in other cells. Phosphorylation of
Ser-184 inhibits proapoptotic function of Bax in A549 human
lung cancer cells [39] whereas phosphorylation of Thr-167 in
Bax activates apoptotic activity in HepG2 human hepatoma
cells [40].
Acinus, apoptotic chromatin condensation inducer in the
nucleus protein (Accession number Q9UKV3), is also a
direct target of Akt and phosphorylation on Ser-422 and Ser-
573 inhibits apoptosis in HEK293 cells, possibly by prevent-
ing caspase-mediated cleavage to a form that is necessary for
chromatin condensation and apoptosis [41]. Acinus was
uniquely seen to be phosphorylated in only the malignant
CA1a cells, according to both the microarray and MS data.
The phosphorylation site that was identified was located on
S1004, as shown in Fig. 8a. Multiple peptides from the pro-
tein were sequenced, some of which were in the aa 800–900
region of the protein. Interestingly it is known that the active
form of the protein is a caspase-cleaved isoform, p17 which
consists of the sequence aa 987–1093. It was thus confirmed
that the unprocessed, and therefore inactive, isoform was
present in the cell line suggesting the absence of apoptotic
chromatin condensation. Suppression of apoptosis may be
instrumental to the malignant nature of the cell line.
3.3.2 Transcriptional regulation
This study showed that several proteins involved in tran-
scriptional regulation were differentially phosphorylated in
the two cell lines. Several histones were more phosphorylat-
ed in CA1a. Histones are typically positively charged to hold
the negatively charged DNA in its condensed form. Phos-
phorylation of histones imparts negative charge so that DNA
is less tightly bound and is thus available for manipulation.
Zfp-36 and nucleolar phosphoprotein p130 are transcrip-
tional regulatory proteins that were seen to be more phos-
phorylated in the malignant CA1a. SAF-B is a scaffold
attachment factor that regulates the formation of the tran-
scriptosomal complex and is also thought to be a corepressor
of the ER, a pivotal factor in breast cancer phenotypes. SAF-B
is known to decrease cell proliferation by reducing tran-
scription of HSP-27. Interestingly this protein was phospho-
rylated in the premalignant AT1.
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Figure 8. (a) Tandem mass
spectrum (with 11 ion series
highlighted) of selected phos-
phopeptide from apoptotic con-
densation inducing factor with
inset showing phosphorylation
difference between AT1 and
CA1a as seen on the microarray.
(b) Microarray image together
with complementary portion of
RP chromatogram where 60S
ribosomal protein L14 was
found to be phosphorylated in
only CA1a.
3.3.3 Protein synthesis
In addition to an increase in transcription-related phospho-
rylation, a parallel increase was seen in translational proteins
in the malignant CA1a cell line compared to the pre-
malignant AT1. Protein identifications as confirmed by MS/
MS showed the expression of larger numbers of ribosomal
proteins in malignant CA1a compared to AT1. These protein
IDs are listed in Table 2 of Supporting Information. The
higher level of expression of ribosome related proteins sug-
gests increased translational activity in the malignant breast
cancer cell line. One of these proteins, 60S ribosomal protein
L14, was confirmed to be phosphorylated on Ser-138. No
phosphorylation sites on this protein have previously been
reported. When comparing the region of the RP chromato-
gram where this protein eluted (Fig. 8b), it can be seen that
distinct and unique peak patterns are evident in both the
CA1a and AT1 cell lines. L14 ribosomal protein was only
identified in the CA1a cell line.
3.3.4 Mitosis
Malignant cells tend to have increased rates of mitosis due to
their proliferative nature. Proteins involved in mitotic spin-
dle formation appeared to be differentially phosphorylated
between the two cell lines. One such protein, Stathmin
(Op18) was uniquely phosphorylated in only the pre-
malignant AT1. This protein regulates the microtubule fila-
ment system by destabilizing microtubule assembly.
Nuclear migration protein (NudC) and microtubule-
associated protein (MAP4) are involved in correct formation
of mitotic spindle. NudC is also involved in cytokinesis and
cell proliferation. A higher expression of phosphorylated
NudC could be indicative of the malignant nature of the
CA1a cell line.
Heat shock protein b-1 is a stress related protein which is
found in the cytoplasm but which colocalizes with mitotic
spindles and migrates to the nucleus during stress.
Increased phosphorylation of this protein in the malignant
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cell line could act as a signal for localization to a particular
part of the cell.
Nuclear envelope disintegration is an integral compo-
nent of mitosis. Lamins provide a framework for the nuclear
envelope and may also indirectly interact with chromatin. In
both cell lines, different forms of lamin were confirmed to be
phosphorylated by MS/MS. Lamins are known to be exten-
sively phosphorylated prior to nuclear disintegration during
the mitosis process. Six phosphorylation sites were found on
lamin A/C in the CA1a malignant cell line, of which two had
not been previously reported (S17 and S18). In addition,
seven sites were found on lamin A/C in the premalignant
AT1 cell line. Three of these sites were the same as the ones
found in the CA1a cell line, while four were unique, of which
one was predicted to be phosphorylated although no experi-
mental evidence has been previously reported. Lamin phos-
phorylation is involved in regulation of lamin interactions
making the differential phosphorylation of this protein be-
tween the two cell lines particularly noteworthy.
3.3.5 Enzymes
Few proteins involved in anabolic or catabolic enzymatic
processes showed phosphorylation differences between AT1
and CA1a cells. However, two examples with relevance to
cancer progression were aromatase and a-enolase. a-Enolase
(MBP1) is a multifunctional enzyme playing a role in many
processes, including glycolysis and growth control. When
MPB1 binds to the c-myc promoter, it acts as a transcrip-
tional repressor. a-Enolase has been implicated as a potential
diagnostic marker for many cancers. In this study, MPB1
was identified in a phosphorylated form in only the AT1 cell
line. Aromatase catalyzes the conversion of testosterone to
estradiol. It has been reported that a kinase activity may be
involved in the regulation of this catalytic process [42]. In this
study, a phosphorylated form of aromatase was uniquely
found in the premalignant AT1 cell line. It is plausible that
phosphorylation of this enzyme renders it inactive. Conse-
quently, the absence of estradiol in the premalignant AT1
may reduce the proliferative capability of the cell line.
3.3.6 Differential expression of proteins in pI range
7.0–6.6
Both the first and second dimension chromatograms sug-
gested increased levels of protein in the higher pH separa-
tion range in the malignant CA1a cell line compared to the
premalignant AT1 cell line. Proteins from the range 7.0–6.6
in the malignant CA1a cell line were analyzed and identified
by MS/MS to see if this increase was specific to any particular
class of proteins. Figure 9 shows a chromatogram of the sec-
ond dimension separation in the 7.0–6.8 pH range. Interest-
ingly, most identified proteins were ribosomal proteins and
other proteins that regulate ribosomal function and genesis
(shown in Table 2 of Supporting Information). A majority of
the proteins identified are known to be phosphorylated and
often times the presence or absence of phosphorylation
determines their location or activation status in the cell. Fur-
thermore, a large number of positive spots in the microarray
(suggesting that the protein in the spot was phosphorylated)
corresponded to the fractions analyzed in this high pH
region. We were unable to locate the phosphorylation sites
on all of these proteins, partly due to the low sequence cov-
erage of most ribosomal proteins due to their low molecular
weights. The theoretical isoelectric points of these ribosomal
proteins are beyond the detection and separation capabilities
of CF (between pH 8 and 11). It is likely that there appeared
to be a higher expression of these proteins in the malignant
CA1a because in fact these proteins were phosphorylated in
the malignant cell line and therefore acquired a lower pI that
made them detectable using the separation scheme used in
these experiments.
4 Concluding remarks
The new hybrid approach presented here has significant
advantages over classical 2-DE/MS/MS and 2-D LC MS/MS
methods. Given the upfront enrichment of a specific class of
proteins, the approach saves considerable time, both overall
and with respect to MS instrument usage. The enrichment
or selection of a subset of the total proteome enables the
focused analysis of that class of protein without having to
sequence and identify a majority of the proteome that may
not be of interest for a specific study. Attempting to extract
information on a subset of proteins from the total proteome
is also less efficient because the proteins of interest may be
diluted, or obscured by the majority. Furthermore, proteins
of low abundance, or extreme pI or solubility characteristics
are more likely to be detected and characterized in enriched
samples. Thus, the method we describe here for the study of
the phosphoproteome enables the identification of a broader
range of phosphoproteins than conventional approaches.
A comparison of premalignant versus malignant breast
cells has not been previously reported using the strategy
described here. In summary, a total of 51 phosphorylation
sites in 27 different proteins were confirmed using MS/MS
and the status of these proteins was found to be specifically
associated with the cellular phenotype. Forty-eight additional
previously known phosphoproteins were identified without
site confirmation. The ontological association of the differ-
entially expressed phosphoproteins included mitosis, apop-
tosis suppression, and translational control. The research
presented here illustrates the use of protein microarrays to-
gether with MS as complementary tools to study phospho-
proteins in complex samples. The microarray is often able to
detect the presence of phosphorylation not detected by MS
without using enrichment techniques. When sample
amounts are too low to permit enrichment the inability to
detect phosphorylation by MS becomes a critical issue, mak-
ing the protein microarray strategy a valuable alternative
means of detecting high to medium abundance phospho-
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Figure 9. Comparison of RP
chromatograms of pH fraction
7.0–6.8 from AT1 and CA1a to il-
lustrate presence of larger
amounts of transcriptional and
translational regulatory proteins
in malignant CA1a but not in
premalignant AT1.
proteins which play a pivotal role in cellular phenotype. Site
mapping by MS would subsequently be needed for complete
characterization; however the strategy outlined above can be
used as an effective and rapid initial screen.
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